RSV Vaccination Shows Strong Protection Against Hospitalization in Nursing Home Residents
A large retrospective cohort of Medicare fee-for-service beneficiaries living in nursing homes found that respiratory syncytial virus vaccination was associated with substantial protection during the first season of availability. In a population defined by advanced age, frailty, and heavy comorbidity burden, the signal was most convincing for preventing RSV-associated hospitalization. The observed effect size is clinically meaningful because nursing home residents often have limited physiologic reserve and can deteriorate quickly after a lower respiratory tract infection.
The study examined claims data from September 10, 2023, through March 30, 2024, and focused on beneficiaries aged 65 years or older who resided in a US nursing home for at least 1 day during the study period. Eligibility also required continuous Medicare Part A and B enrollment for 365 days before the index date and continuous Part D enrollment beginning June 21, 2023. Investigators built separate cohorts for four outcomes: RSV-associated hospitalization, RSV-associated death, severe RSV-associated outcomes, and RSV-associated thromboembolic events. Exposure was defined by Medicare Part D claims for RSV vaccination, and outcome ascertainment relied on claims-based diagnostic coding.
Among 597,430 included beneficiaries, 66% were female and the median age was 82 years, with an interquartile range of 75 to 88 years. Those baseline characteristics matter because this is not a healthier older-adult population with broad physiologic reserve; it is a cohort in which even modest respiratory illness can precipitate hospitalization, critical illness, or death. In that context, a vaccine effectiveness estimate of 73% against RSV-associated hospitalization is a major finding.
The 73% vaccine effectiveness estimate carried a 95% confidence interval of 65% to 79%, suggesting a robust association rather than a fragile point estimate. The protective effect did not appear uniform across all subgroups, however. Among beneficiaries aged 65 to 74 years, vaccine effectiveness was 60% with a 95% confidence interval of 35% to 76%. In beneficiaries aged 75 years or older, effectiveness was 75% with a 95% confidence interval of 67% to 82%.
The age-stratified pattern is clinically interesting because it runs counter to the usual expectation that older age sharply erodes vaccine performance. In this cohort, protection remained substantial in the oldest beneficiaries, the very group most likely to experience severe RSV complications. The finding fits with a prevention strategy aimed not at eliminating every infection, but at reducing the probability that a respiratory infection pushes a frail patient into the hospital.
Protection also extended to short-stay residents, among whom vaccine effectiveness against RSV-associated hospitalization was 67% with a 95% confidence interval of 55% to 76%. Short-stay residents are often transitioning through post-acute care or rehabilitation, and their clinical course can be especially vulnerable to an acute viral insult. A reduction in hospitalization risk in that subgroup suggests the vaccine may retain value even when residency duration is limited and baseline medical complexity remains high.
Claims-Based Endpoints Point to a High-Risk Population
The study’s design used multivariable Cox proportional hazards models to compare time to first outcomes among vaccinated and unvaccinated beneficiaries, and vaccine effectiveness was calculated as 1 minus the hazard ratio, multiplied by 100%. Because this was a claims-based analysis, the endpoints depended on ICD-10 coding and administrative data rather than adjudicated clinical events. That approach can support large-scale surveillance, but it also means the estimates reflect real-world coding practices and health care utilization patterns, not laboratory-confirmed virologic surveillance alone.
Even with that limitation, the consistency of the hospitalization result gives the analysis practical weight. Nursing home residents represent a population in which RSV prevention has been difficult to prioritize because influenza and COVID-19 have historically dominated seasonal respiratory planning. This dataset places RSV on firmer ground as a preventable cause of acute care use in long-term care settings.
The abstract also specified outcomes beyond hospitalization, including RSV-associated death, severe RSV-associated outcomes defined by intensive care unit or critical care unit admission, medical ventilator use, or RSV-associated death, and RSV-associated thromboembolic events. The available excerpt does not provide the numerical estimates for those endpoints, so no additional effect size can be stated here without overstepping the source data. Still, the inclusion of those outcomes signals a deliberate effort to examine whether vaccination influences not just infection-driven admissions, but the downstream complications that drive morbidity and mortality in very old adults.
What the Effect Size Means at the Bedside
For clinicians caring for nursing home residents, the central takeaway is direct: RSV vaccination was associated with a markedly lower risk of RSV-related hospitalization in a cohort that closely resembles the patients at highest risk of severe winter respiratory disease. The finding supports vaccination as a preventive tool in long-term care, where outbreaks can spread quickly and where hospitalization often triggers further functional decline.
The result also offers a practical framework for counseling families and surrogate decision-makers. In very old adults, vaccine discussions often hinge on whether prevention is likely to translate into a meaningful reduction in acute illness rather than an abstract immunologic benefit. A 73% relative reduction in RSV-associated hospitalization provides a concrete rationale for immunization in settings where hospitalization can mean delirium, deconditioning, pressure injury risk, and prolonged dependence.
The study does not answer every operational question. Claims data cannot fully separate biologic vaccine failure from differences in care-seeking, coding, or residual confounding. The excerpt provided does not include information on vaccine product-specific performance, timing from vaccination to protection, or the numerical results for death and other severe outcomes. Those gaps leave room for further analysis, especially in subgroups with the highest frailty burden and in residents with repeated hospital exposure.
Even so, the overall message is difficult to ignore. In a Medicare nursing home population numbering nearly 600,000 beneficiaries, RSV vaccination aligned with a sizable drop in hospitalization risk during the first season in which the vaccine was available. For long-term care clinicians and public health teams, the finding strengthens the case for treating RSV prevention as part of routine seasonal respiratory protection rather than as a secondary consideration.
The unanswered issues now sit at the level of implementation: how quickly coverage can be expanded in nursing homes, how protection performs over multiple seasons, and whether the hospitalization benefit extends with the same strength to death and other severe outcomes. Those questions will determine how fully this early protection translates into durable practice change.